Company Information

Agenus has 22 programs in clinical development, between our own pipeline and our strategic partnerships, including three programs currently in Phase 3 clinical trials. Our goal is to build shareholder value by bringing cutting-edge immune-therapies to patients, harnessing the power of the immune system to optimize the treatment of patients with cancer and infectious diseases and to improve the prevention of disease.

Stock Chart

NASDAQ: AGEN
$ 6.11 -0.03 (-0.49%)
Volume: 876.1k
4:00 p.m. ET on August 09, 2016
Minimum 15 minute delay.